WO2023047338 - PRODRUG INCORPORATED sgRNA SYNTHESIS
National phase entry is expected:
Publication Number
WO/2023/047338
Publication Date
30.03.2023
International Application No.
PCT/IB2022/058996
International Filing Date
23.09.2022
Title **
[English]
PRODRUG INCORPORATED sgRNA SYNTHESIS
[French]
SYNTHÈSE DE SGRNA SYNTHÉTIQUE PRODRUG
Applicants **
CRISPR THERAPEUTICS AG
Baarerstrasse 14
6300 Zug, CH
Inventors
DAS, Rajat
610 Main Street
Cambridge, Massachusetts 02139, US
SANKARAN, Ganapathy
610 Main Street
Cambridge, Massachusetts 02139, US
Priority Data
63/248,272
24.09.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2560 | |
| EPO | Filing, Examination | 21122 | |
| Japan | Filing | 595 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 14510 |
Total: 39362 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Disclosed herein include guide RNA (gRNA), such as single gRNA (sgRNA), and compositions thereof, comprising 2'-O-methyldithiomethyl modified sugar moieties which can be reduced to 2'-O-methanethiol groups in the reducing environment of cells and then converted (e.g., spontaneously converted) to 2'-OH. The resultant gRNA can bind to and direct the activity of an RNA-guided endonuclease (e.g., Cas9).[French]
La présente invention comprend un ARN guide (ARNg), tel qu'un ARNg unique (ARNsg), et des compositions de celui-ci, comprenant des fractions de sucre modifiées en 2'-O-méthyldithiométhyle qui peuvent être réduites en groupes 2'-O-méthanethiol dans l'environnement réducteur des cellules et ensuite converties (par exemple, spontanément) en 2'-OH. L'ARNg résultant peut se lier à une endonucléase guidée par ARN (par exemple, Cas9) et diriger son activité.